Business ❯ Healthcare ❯ Pharmaceuticals
Clinical Trials GLP-1 Drugs Weight Loss Drugs Eli Lilly Acquisitions Oncology Obesity Treatments Obesity Drugs Market Performance Weight Loss Medications Novo Nordisk Monoclonal Antibodies Eli Lilly and Company Cancer Treatment Novo Nordisk A/S Diabetes Treatments AstraZeneca Immunology Rare Diseases Weight Management Sales Performance GLP-1 Medications Market Competition Alzheimer's Disease AbbVie Partnerships Eli Lilly Products Market Strategies Anti-Obesity Drugs Tirzepatide FDA Regulations Multiple Sclerosis Treatments Investment Plans Cancer Treatments Artificial Intelligence Merck Antibody Drug Conjugates Metsera Neuroplastogenic Therapeutics Research and Development Casgevy New Drug Application Obesity and Diabetes Drugs Endocrinology Patent Issues Chronic Myeloid Leukemia Obesity and Diabetes Care Vykat XR Pfizer FDA Approval Therapy Candidates RELYVRIO Sarepta Therapeutics Orforglipron Antiviral Technology Alzheimer's Treatments Commercialization Rheumatoid Arthritis Pulmonary Hypertension Innovative Treatments Infectious Diseases T Cell Engagers Market Capitalization Skyrizi Tyrosine Kinase Inhibitors AbbVie Inc. Oral Weight Loss Pill Breyanzi Regulatory Approval Merck & Co., Inc. Concussion Treatment Wockhardt Silevertinib Rigel Pharmaceuticals Regeneron Pharmaceuticals Springworks Therapeutics Biologic Medicines Flu Antivirals Clinical Research AI in Pharmaceuticals Blockbuster Drugs Vertex Pharmaceuticals Weight Loss Treatments AI Integration Personalized Medicine ImmunityBio Biomarker Discovery Autoimmune Treatments Autoimmune Drugs COPD Treatment Parabilis Medicines Innovative Drugs Injectable Treatments Briumvi Efficacy Studies Biotherapeutics Weight Loss Treatment DPLEx100 Preventative Therapies Stelara
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
The company says it will use its global development and commercial reach to advance Apogee’s antibody programs targeting IL-13 and a combo that blocks TSLP.
